-

Half-Year Liquidity Contract Statement for Valerio Therapeutics

PARIS--(BUSINESS WIRE)--Regulatory News:

Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO)

Under the liquidity contract entered into between Valerio Therapeutics and Kepler Cheuvreux, the following resources appeared on the liquidity account on December 31st 2023:

- 368,174 shares
- € 144,918.05

- Number of executions on buy side on semester: 324
- Number of executions on sell side on semester: 244
- Traded volume on buy side on semester: 304,205 shares for € 69,976.87
- Traded volume on sell side on semester: 223,191 shares for € 56,117.81

As a reminder :

  • the following resources appeared on the last half year statement on 30 June 2023 on the liquidity account:

- 287,160 shares
- € 156,554.06

- Number of executions on buy side on semester: 509
- Number of executions on sell side on semester: 492
- Traded volume on buy side on semester: 634,648 shares for € 258,705.74
- Traded volume on sell side on semester: 923,185 shares for € 402,719.91

  • the following resources appeared on the liquidity account when the activity started:

- 87,612 shares
- € 196,423.24

The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22nd 2021 renewing the implementation of liquidity contracts for shares as an accepted market practice.

Contacts

Valerio Therapeutics S.A.

Valerio Therapeutics

BOURSE:ALVIO
Release Versions
EnglishFrench

Contacts

Valerio Therapeutics S.A.

More News From Valerio Therapeutics

Valerio Therapeutics Announces the Appointment of Professor Eric Vivier as Observer to Its Board of Directors

PARIS--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics (“Valerio Therapeutics” or the “Company”) (Euronext Growth Paris: ALVIO) announces the appointment of Professor Eric Vivier as an Observer to its Board of Directors. His nomination as a Director will be submitted to shareholders at the Company’s next general meeting. Professor Eric Vivier works within Aix Marseille University and Assistance Publique-Hôpitaux de Marseille (AP-HM) and is also a professor at École Polytechnique (X). He...

Valerio Therapeutics: Postponement of 2024 Annual Financial Report Publication and the Approval of Financial Statements

PARIS--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO) (the “Company”) announces the postponement of the publication of its 2024 annual financial report, initially scheduled for April 30, 2025, as well as the finalization and approval of its statutory and consolidated financial statements for 2024. The Company is facing significant difficulties in accessing the accounting records of its U.S. subsidiary, Valerio Therapeutics Inc. Although the assets rel...

VALERIO THERAPEUTICS: List of the Board Members Positions Held in Other Companies as of March 19, 2025

PARIS--(BUSINESS WIRE)--Regulatory News: VALERIO THERAPEUTICS (Paris:ALVIO):  Name of Director Other offices and functions   Julien MIARA Chief Executive Officer and Director   Managing Director at Invus Director of Sensorion Director of Versity   Jacques MALLET Director and Chairman of the Board   Chairman of Gamma-X Corporate Advisory Director of Technoflex Director of the Fournier Majoie Foundation   FINANCIERE DE LA MONTAGNE, represented by Nicolas TREBOUTA Director   Manager of SARL Financ...
Back to Newsroom